Literature DB >> 1170585

Comparative analgesic activity of various naturally occurring cannabinoids in mice and rats.

R D Sofia, H B Vassar, L C Knobloch.   

Abstract

The analgesic effectiveness of delta-9-tetrahydrocannabinol (THC), a crude marihuana extract (CME), cannabinol (CBN), cannabidiol (CBD), morphine SO-4 and aspirin following oral administration was directly compared in mice using the acetic-induced writhing and hot plate tests and the Randall-Selitto paw pressure test in rats. THC and morphine were equipotent in all tests except that morphine was significantly more potent in elevating pain threshold in the uninflamed rat hind paw. In terms of THC content, CME was nearly equipotent in the hot plate and Randall-Selitto tests, but was 3 times more potent in the acetic acid writhing test. On the other hand, CBN, like aspirin, was only effective in reducing writhing frequency in mice (3 times more potent than aspirin) and raising pain threshold of the inflamed hind paw of the rat (equipotent with aspirin). CBD did not display a significantly analgesic effect in any of the test systems used. The results of this investigation seem to suggest that both THC and CME possess narcotic-like analgesic activity similar to morphine, while CBN appears to be a non-narcotic type analgesic like aspirin.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1170585     DOI: 10.1007/bf00421466

Source DB:  PubMed          Journal:  Psychopharmacologia


  22 in total

1.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

Review 2.  Role of cannabinoids in the management of neuropathic pain.

Authors:  M Isabel Martín Fontelles; Carlos Goicoechea García
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Adverse effects of incorporating ketoprofen into established rodent studies.

Authors:  Tennille K Lamon; Elizabeth J Browder; Farida Sohrabji; Melanie Ihrig
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-07       Impact factor: 1.232

4.  Cannabidiol-Δ9-tetrahydrocannabinol interactions on acute pain and locomotor activity.

Authors:  Stevie C Britch; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Drug Alcohol Depend       Date:  2017-04-15       Impact factor: 4.492

5.  Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol.

Authors:  Nicholas Z Greene; Jenny L Wiley; Zhihao Yu; Brian H Clowers; Rebecca M Craft
Journal:  Psychopharmacology (Berl)       Date:  2018-09-20       Impact factor: 4.530

6.  Possible mediation of catecholaminergic pathways in the antinociceptive effect of an extract of Cannabis sativa L.

Authors:  S Ferri; E Cavicchini; P Romualdi; E Speroni; G Murari
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

7.  Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions.

Authors:  P J Welburn; G A Starmer; G B Chesher; D M Jackson
Journal:  Psychopharmacologia       Date:  1976

8.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

9.  The effects of morphine and delta-9-tetrahydrocannabinol on motor activity in rats.

Authors:  F C Tulunay; I H Ayhan; S B Sparber
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  Interactions among the cannabinoids in the antagonism of the abdominal constriction response in the mouse.

Authors:  J Sanders; D M Jackson; G A Starmer
Journal:  Psychopharmacology (Berl)       Date:  1979-03-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.